Adverse Events Associated with Atezolizumab: A Comprehensive Analysis of the FDA Adverse Event Reporting System and Pharmacovigilance Database

• Atezolizumab is associated with a spectrum of immune-related adverse events, with pneumonitis being the most frequently reported serious event. • Patients with non-small cell lung cancer (NSCLC) exhibit a higher risk of atezolizumab-induced pneumonitis compared to other tumor types. • Rare but severe adverse events such as myocarditis and myasthenia gravis were identified as potential safety signals. • The study underscores the necessity for proactive monitoring and management of immune-related toxicities in atezolizumab-treated patients.